The mixture of Ipamorelin and CJC-1295 NO DAC represents a synergistic combination of two peptides frequently studied in the scientific community for their potential in the areas of growth, regeneration and neuroendocrine signaling.
Contents
5 mg Ipamorelin + 5 mg CJC-1295 NO DAC
Measured values (HPLC)
5.75 mg (Ipamorelin), 5.53 mg (CJC-1295 NO DAC)
Purity (HPLC)
98% (both components)
Packaging
10 mg (5+5) in a glass vial
Storage
Dry, dark, temperature up to 8 °C
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
Ipamorelin acetate, CJC-1295 w/o DAC
In laboratory studies, the Ipamorelin/CJC-1295 NO DAC mixture has been associated with tracking in areas such as:
- supporting the secretion of growth hormone (GH),
- monitoring body composition and anabolic markers,
- improvement of regenerative processes and tissue renewal,
- neuroendocrine functions and memory,
- monitoring IGF-1 levels during peptide protocols.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is the combination Ipamorelin / CJC-1295 NO DAC
Ipamorelin is a selective GHRP-agonist that stimulates growth hormone release via the ghrelin receptor. CJC-1295 without DAC (Drug Affinity Complex) is a modified GHRH analog that promotes pulsatile release of GH without prolonging its half-life. Their combination is being studied as a synergistic method to influence GH production in a natural rhythm without suppressing endogenous secretion.
How their injectable combination works
When administered by sc or im injection, Ipamorelin binds to the ghrelin receptor in the pituitary gland, while CJC-1295 NO DAC stimulates the release of GHRH. The combination results in a synergistic GH pulse that mimics natural secretory patterns. The advantage of this combination is the absence of prolactinemic side effects and a lower risk of receptor desensitization.
Effects studied
-
Increase in GH and IGF-1 levels: Observed in both animals and humans when monitoring growth markers.
-
Regeneration: Supporting the repair of muscles, tendons and joints in damaged tissues.
-
Sleep cycles: GH is associated with deep sleep and pulses can support sleep architecture.
-
Neuroendocrine effects: Possible effect on memory, motivation, and hypothalamic-pituitary axis function.
-
Recombination with other GHRPs: Frequently studied protocols with synergistic effects.
Dosage in studies
The values listed are derived solely from research studies and are not intended for real-world use outside of a laboratory environment.
-
Dosage: 100 – 300 μg of each ingredient
-
Form: subcutaneous
-
Frequency: 1 – 3 times a day (morning, after training, before bed)
-
Duration: 4 – 12 week cycles in monitored protocols
Possible side effects
- Rarely, itching or tenderness at the injection site
- Possible temporary water retention
- Appetite changes (especially when combined with GHRP-6)
Resources
- Ghigo E. et al. (1999). Growth hormone-releasing peptides
- Teichman SL et al. (2006). CJC-1295 enhances GH and IGF-1 secretion
- Arvat E. et al. (1998). Endocrine activities of Ipamorelin
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
